author-photo

Donna E. Hogge

University of British Columbia

228

Papers

8229

Citations

Citation Trend

Filter By

Papers (151) Sort By

Journal Conference Others

CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial

2021 The Lancet Haematology
Show All
- Source
- Cite
- Save
Citations (4)
Continuous Alloreactive T Cell Depletion and Regulatory T Cell Expansion for the Treatment of Steroid- Refractory or Dependent Chronic GVHD – a Multicentre Phase II Clinical Trial (CARE Trial)

2021
Show All
- Source
- Cite
- Save
Citations (0)
Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses.

2021 Blood Advances
Show All
- Source
- Cite
- Save
Citations (5)
Day 14 Bone Marrow Evaluation during Acute Myeloid Leukemia Induction in a Real-World Canadian Cohort

2020 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
FIVE-YEAR FINAL RESULTS OF A PHASE 3 STUDY OF CPX-351 VERSUS 7+3 IN OLDER ADULTS WITH NEWLY DIAGNOSED HIGH-RISK/SECONDARY ACUTE MYELOID LEUKEMIA (AML)

2020 Hematology, Transfusion and Cell Therapy
Show All
- Source
- Cite
- Save
Citations (2)
Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

2020 Biology of Blood and Marrow Transplantation
Show All
- Source
- Cite
- Save
Citations (1)
Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

2019 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia

2019 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (5)
Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylating Agent Exposure Who Achieved Remission

2019 Blood
Show All
- Source
- Cite
- Save
Citations (3)
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (387)